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process of synovial joints (Fig. 1). Diverse insults
to any joint component may trigger OA, and all
joint tissues take part in the response. In most
cases, OA compensates for the insult. In a minor-
ity, either due to overwhelming insult or to poor
repair, the joint decompensates, progressing to
further damage and increasing association with
symptoms and disability. The following are worthy
of emphasis:
- The observed marked heterogeneity in clinical
presentation and outcome is to be expected
- Risk factors for development may di#er from
risk factors for progression
- The relative importance of di#erent joint tis-
sues, in terms of site of initiation and in propor-
tional tissue response, may vary between
individuals and between joint sites.
- Extrapolation from one OA site to another
is problematic for risk factors, pathogenesis,
treatment response and outcome.319The consequences of synovial involvement
There are varying degrees of synovial hyperpla-
sia and increased cytokine production in OA.
Whether synovitis is a primary insult or more
commonly is secondary (e.g., to cartilage frag-
ments and calcium crystals—‘debris’ synovitis) is
unclear. Certainly histologic abnormality and
increased cytokine production occurs in synovium
from subjects with knee pain, normal X-rays, but
arthroscopically abnormal cartilage (‘early’ OA);
these changes increase in severe OA [1]. Possible
consequences of this mild-modest synovitis
include:
- Deleterious local e#ects on cartilage and bone
- Pain, through chemical sensitization of nocicep-
tor fibers and intra-articular hypertension
(itself potentially injurious)
- Muscle inhibition and enhanced type II fiber
atrophy
- Altered joint proprioception with subsequent
biomechanical compromise
Changes in the capsule (outer synovium) and its
ligaments are also relevant. Instability is not a
feature of mild-moderate OA but may develop with
severe deformity and attrition. Capsular thicken-
ing and contraction may thus aid stability as joint
shape alters.
Recognition of mild-modest synovial
involvement in OA
Sti#ness, stress pain, warmth, e#usion and wide-
spread joint-line tenderness are thought to reflect
synovitis. Summated scores of these clinical fea-
tures are used but are likely to be insensitive.
Visual scoring and histologic grading of synovium
may approach a gold standard, but arthroscopic
biopsy is invasive and unsuited for serial monitor-
ing. Some synovial fluid measures (e.g., chondroi-
tin sulphate 7-D-4) vary with clinically assessedInsults
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FIG. 1. Proposed repair process of synovial joints for
adequate repair (compensation) or osteoarthritis
(decompensation).
320 Doherty: Synovial inflammation and osteoarthritis progressioninflammation. Serum C-reactive protein (CRP) is
elevated in large joint OA but only in the low
range of 1–10 mg/L. Serum hyaluronan levels are
thought to reflect primarily synovial activity. The
role of MRI and other imaging in quantifying
synovial abnormality remains to be determined.
Does synovial reaction correlate with OA
outcome?
Increased risk of radiographic progression at the
knee has been associated with elevations of serum
hyaluronan and serum CRP. Even clinically-
assessed warmth and e#usion associate with
increased risk (e.g., adjusted odds ratio for warmth
2.08 [2]), as does the presence of calcium pyro-
phosphate crystals (possibly relating to their
inflammatory potential).
Control of synovitis in OA can improve symp-
toms and function. Knee lavage may give benefit
for months, intra-articular steroid for just a few
weeks. Data are conflicting as to whether inflam-
matory parameters predict response. Whether con-
trol of synovitis influences structural outcome is
an important unanswered question.
The effect of NSAIDs
The rationale for nonsteroidal antiinflammatory
drugs (NSAIDs) in OA is pain relief. Although
widely prescribed for OA, their usual e#ect size
(e.g., for pain visual analog scale, VAS) is only in
210–20%. Whether NSAIDs are more e#ective
than simple analgesics in OA is questioned by the
following:- Little di#erence between acetaminophen, low-
dose ibuprofen and high (anti-inflammatory)
dose of ibuprofen for short-term OA pain relief
- Inflammatory symptoms and signs are poor pre-
dictors of response to NSAID in OA
- Many OA patients stop an individual NSAID
after several months
- Several studies show the ease with which
patients discontinue their NSAID if given
alternative strategies
Given their side-e#ect profile, especially in
the elderly, NSAIDs are low on the list of
interventions in Management Guidelines.
NSAIDs have biochemical e#ects on OA, and
possibly normal, joints. For example, synovial fluid
prostaglandin and interleukin (IL)-6 levels
decrease, but tumor necrosis factor (TNF) levels
increase after two weeks of oral NSAID [3]. The
few studies examining structural e#ects of
NSAIDs on hip or knee OA suggest detrimental
e#ects on cartilage and bone. Inclusion of synovial
assessments in further clinical studies seems
justified.
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